Regulation and function of pyruvate kinase M2 in cancer

Cancer Letters

Volumn 339, Issue 2, 2013, Pages 153-158

  Yang, Weiwei ^a   Lu, Zhimin ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene expression; PKM2; The Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PYRUVATE KINASE; PYRUVATE KINASE M2; PYRUVATE KINASE M2 INHIBITOR; SHIKONIN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER METABOLISM; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL NUCLEUS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REGULATORY MECHANISM; SHORT SURVEY; TRANSCRIPTION REGULATION;

EID: 84883751792     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.008     Document Type: Review

References (62)

1. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
2. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006, 66:8927-8930.
3. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
4. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
5. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
6. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
7. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
8. Altenberg B., Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84:1014-1020.
9. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., Sellers W.R. MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
10. Noguchi T., Inoue H., Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 1986, 261:13807-13812.
11. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
12. Corcoran E., Phelan J.J., Fottrell P.F. Purification and properties of pyruvate kinase from human lung. Biochim. Biophys. Acta 1976, 446:96-104.
13. Tolle S.W., Dyson R.D., Newburgh R.W., Cardenas J.M. Pyruvate kinase isozymes in neurons, glia, neuroblastoma, and glioblastoma. J. Neurochem. 1976, 27:1355-1360.
14. Reinacher M., Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell Pathol. Incl. Mol. Pathol. 1981, 37:79-88.
15. Schering B., Eigenbrodt E., Linder D., Schoner W. Purification and properties of pyruvate kinase type M2 from rat lung. Biochim. Biophys. Acta 1982, 717:337-347.
16. MacDonald M.J., Chang C.M. Pancreatic islets contain the M2 isoenzyme of pyruvate kinase. Its phosphorylation has no effect on enzyme activity. Mol. Cell. Biochem. 1985, 68:115-120.
17. Brinck U., Eigenbrodt E., Oehmke M., Mazurek S., Fischer G. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 1994, 424:177-185.
18. Mazurek S., Boschek C.B., Hugo F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
19. Noguchi T., Yamada K., Inoue H., Matsuda T., Tanaka T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 1987, 262:14366-14371.
20. Wang Z., Takenaka M., Imai E., Yamada K., Tanaka T., Noguchi T. Transcriptional regulatory regions for expression of the rat pyruvate kinase M gene. Eur. J. Biochem. 1994, 220:301-307.
21. Yamada K., Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem. J. 1999, 337(Pt 1):1-11.
22. Netzker R., Weigert C., Brand K. Role of the stimulatory proteins Sp1 and Sp3 in the regulation of transcription of the rat pyruvate kinase M gene. Eur. J. Biochem. 1997, 245:174-181.
23. Schafer D., Hamm-Kunzelmann B., Brand K. Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett. 1997, 417:325-328.
24. Discher D.J., Bishopric N.H., Wu X., Peterson C.A., Webster K.A. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem. 1998, 273:26087-26093.
25. Schafer D., Hamm-Kunzelmann B., Hermfisse U., Brand K. Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. FEBS Lett. 1996, 391:35-38.
26. Marshall S., Bacote V., Traxinger R.R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 1991, 266:4706-4712.
27. Panasyuk G., Espeillac C., Chauvin C., Pradelli L.A., Horie Y., Suzuki A., Annicotte J.S., Fajas L., Foretz M., Verdeguer F., Pontoglio M., Ferre P., Scoazec J.Y., Birnbaum M.J., Ricci J.E., Pende M. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 2012, 3:672.
28. Wong T.S., Liu X.B., Chung-Wai Ho A., Po-Wing Yuen A., Wai-Man Ng R., Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123:251-257.
29. Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., Wang Y., Jing Y., Yang H., Chen R., Chang L., Zhang Y., Goto J., Onda H., Chen T., Wang M.R., Lu Y., You H., Kwiatkowski D., Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 2011, 108:4129-4134.
30. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N., Pandey A., Semenza G.L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
31. Pescador N., Cuevas Y., Naranjo S., Alcaide M., Villar D., Landazuri M.O., Del Peso L. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem. J. 2005, 390:189-197.
32. Yang W., Xia Y., Cao Y., Zheng Y., Bu W., Zhang L., You M.J., Koh M.Y., Cote G., Aldape K., Li Y., Verma I.M., Chiao P.J., Lu Z. EGFR-Induced and PKCepsilon Monoubiquitylation-Dependent NF-kappaB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis. Mol. Cell 2012, 48:771-784.
33. Lu Z. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer 2012, 31:5-7.
34. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., Lyssiotis C.A., Aldape K., Cantley L.C., Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14:1295-1304.
35. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp. Proc. 2007, 99-124.
36. Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog. 1992, 3:91-115.
37. Dombrauckas J.D., Santarsiero B.D., Mesecar A.D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
38. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
39. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
40. de Koning T.J., Snell K., Duran M., Berger R., Poll-The B.T., Surtees R. L-serine in disease and development. Biochem. J. 2003, 371:653-661.
41. Chaneton B., Hillmann P., Zheng L., Martin A.C., Maddocks O.D., Chokkathukalam A., Coyle J.E., Jankevics A., Holding F.P., Vousden K.H., Frezza C., O'Reilly M., Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012, 491:458-462.
42. Keller K.E., Tan I.S., Lee Y.S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338:1069-1072.
43. Lu Z., Hunter T. Degradation of activated protein kinases by ubiquitination. Annu. Rev. Biochem. 2009, 78:435-475.
44. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., Dong S., Lonial S., Wang X., Chen G.Z., Xie J., Gu T.L., Polakiewicz R.D., Roesel J.L., Boggon T.J., Khuri F.R., Gilliland D.G., Cantley L.C., Kaufman J., Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal 2009, 2:ra73.
45. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., Yao J., Zhou L., Zeng Y., Li H., Li Y., Shi J., An W., Hancock S.M., He F., Qin L., Chin J., Yang P., Chen X., Lei Q., Xiong Y., Guan K.L. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327:1000-1004.
46. Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y., Li Z., Xu Y., Wang G., Huang Y., Xiong Y., Guan K.L., Lei Q.Y. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
47. Anastasiou D., Poulogiannis G., Asara J.M., Boxer M.B., Jiang J.K., Shen M., Bellinger G., Sasaki A.T., Locasale J.W., Auld D.S., Thomas C.J., Vander Heiden M.G., Cantley L.C. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
48. Wellen K.E., Thompson C.B. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol. Cell 2010, 40:323-332.
49. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., Aldape K., Hunter T., Alfred Yung W.K., Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
50. Lu Z. PKM2 functions as a histone kinase. Cell Cycle 2012, 11:4101-4102.
51. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
52. Ubersax J.A., Ferrell J.E. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 2007, 8:530-541.
53. Stetak A., Veress R., Ovadi J., Csermely P., Keri G., Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007, 67:1602-1608.
54. Hoshino A., Hirst J.A., Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J. Biol. Chem. 2007, 282:17706-17711.
55. Spoden G.A., Morandell D., Ehehalt D., Fiedler M., Jansen-Durr P., Hermann M., Zwerschke W. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 2009, 107:293-302.
56. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
57. Kefas B., Comeau L., Erdle N., Montgomery E., Amos S., Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-oncology 2010, 12:1102-1112.
58. Vander Heiden M.G., Christofk H.R., Schuman E., Subtelny A.O., Sharfi H., Harlow E.E., Xian J., Cantley L.C. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 2010, 79:1118-1124.
59. Chen J., Xie J., Jiang Z., Wang B., Wang Y., Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011, 30:4297-4306.
60. Porporato P.E., Dhup S., Dadhich R.K., Copetti T., Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2011, 2:49.
61. Guo C., Linton A., Jalaie M., et al. Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioor. Med. Chem. Lett. 2013, 23:3358-3363.
62. Anastasiou D., Yu Y., Israelsen W.J., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature chemical biology 2012, 8:839-847.